FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

CAR T Cell Product Development Guidance

FDA publishes a draft guidance with CAR T cell-specific recommendations about chemistry, manufacturing, and control; pharmacology and toxicology; and ...

Human Drugs

FDA Approves Mylan Symbicort Generic

FDA approves Mylans generic Symbicort for asthma and COPD patients.

FDA General

Bill with FDA Responsibilities Moves to Senate Floor

A Senate pandemic-related bill that outlines many new FDA responsibilities heads to the Senate floor for a vote after being marked-up 3/15 by Health, ...

Human Drugs

Pfizer/BioNTech File for 2nd Covid Vaccine Booster

Pfizer and BioNTech file an Emergency Use Authorization application for a second Covid-19 vaccine booster dose in adults 65 years of age and older who...

Federal Register

FDA Revokes 2 No-Longer Used Covid Tests

Federal Register notice: FDA revokes the Emergency Use Authorizations issued to LifeHope Labs for the LifeHope 2019-nCoV Real-Time RTPCR Diagnostic Pa...

Federal Register

Guide on Foreign Supplier Program

Federal Register notice: FDA makes available a final guidance entitled Current Good Manufacturing Practice and Preventive Controls, Foreign Supplier V...

Biologics

Complete Response on Fasenra Supplemental BLA

FDA sends AstraZeneca a complete response letter on its supplemental BLA for Fasenra (benralizumab) for patients with inadequately controlled chronic ...

Federal Register

GE Reagent Not Withdrawn for Safety/Efficacy

Federal Register notice: FDA determines that GE Healthcares MPI DMSA kidney reagent (Technetium Tc-99m Succimer Kit), Injectable, was not withdrawn fr...

Medical Devices

Baxter Class 1 Recall on Sigma Infusion Pumps

FDA classifies as Class 1 a Baxter Healthcare recall of its Sigma Spectrum Infusion Pumps with Master Drug Library (Version 8) and Spectrum IQ Infusio...

Human Drugs

Incyte Review Extension on Opzelura Cream

FDA extends by three months its review of Incytes supplemental NDA for Opzelura (ruxolitinib) cream for treating vitiligo.